Q2 2025 Neurocrine Biosciences Inc Earnings Call Transcript
Key Points
- Neurocrine Biosciences Inc (NBIX) reported $682 million in net product sales for Q2 2025, representing a 17% year-over-year growth.
- The launch of CRENESSITY has been strong, with sales growing from $15 million in Q1 2025 to $53 million in Q2 2025, reflecting strong early adoption.
- INGREZZA achieved $624 million in sales for Q2 2025, with a record number of new patient starts and total prescriptions.
- The company has a robust and diversified neuroscience-focused pipeline, with multiple Phase 3 programs initiated within a single calendar year.
- Neurocrine Biosciences Inc (NBIX) has a strong balance sheet with $1.8 billion in cash, positioning it well to support commercial and clinical development strategies for continued growth.
- The company expects a negative 5% price decline for INGREZZA in 2025 due to contracting, impacting near-term dollar share despite volume growth.
- Valbenazine did not meet the primary endpoint in a study for adjunctive treatment of schizophrenia, though it provided valuable insights for future programs.
- The company has increased SG&A GAAP and non-GAAP operating expense guidance by $25 million to support continued sales growth, indicating higher operational costs.
- Despite strong early adoption, CRENESSITY's long-term market penetration and growth remain uncertain, with most prescribers having initiated treatment for only one or two patients.
- The company faces potential challenges with the IRA implications and competitive dynamics in the market, which could impact future pricing and access strategies.
Good day, everyone, and welcome to Neurocrine Biosciences second-quarter 2025 results conference.. (Operator Instructions)
Please note this call may be recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead, sir.
Thank you and happy Wednesday, everyone. Welcome to Neurocrine Biosciences' second-quarter 2025 earnings call. With me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Eiry Roberts; and for first time as Chief Medical Officer, Sanjay Keswani.
During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we will jump into Q&A. I now turn the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
